INTRA-CELLULAR THERAPIES, INC. for INTRA-CELLULAR THERAPIES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA). Part D 6 protected classes policy. Medicaid Drug Rebate Program Rule - Provisions regarding "stacking" of rebates and discounts.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Health Issues HCR
HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Taxation/Internal Revenue Code TAX
HR 3938/S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax credit amortization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.